CA2021767C - Method for preparing a pharmaceutical composition in the form of microparticles - Google Patents
Method for preparing a pharmaceutical composition in the form of microparticlesInfo
- Publication number
- CA2021767C CA2021767C CA002021767A CA2021767A CA2021767C CA 2021767 C CA2021767 C CA 2021767C CA 002021767 A CA002021767 A CA 002021767A CA 2021767 A CA2021767 A CA 2021767A CA 2021767 C CA2021767 C CA 2021767C
- Authority
- CA
- Canada
- Prior art keywords
- active substance
- copolymer
- microparticles
- mixture
- grain size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Abstract
A method for preparing a pharmaceutical composition in the form of microparticles, the composition thus obtained and its use for preparing injectable suspensions.
Description
%o%~767 SUMMARY OF T~E lNv~ ON
More precisely, the object of the invention is a method for preparing a pharmaceutical composition which is aimed at providing a prolonged and a controlled release of a medicamentous substance, which is obtained in the form of microparticles of a copolymer of lactic and of glycolic acids, and which incorporates, as the active substance, the pamoate, tannate, stearate or palmitate of a natural or of a synthetic peptide and, more particularly, of a peptide comprising 3 to 45 amino acids.
STATE OF TXE ART
Various solutions have been proposed to this day for preparing compositions ensuring a prolonged and a controlled release of medicamentous substances, which are based on the preparation of biodegradable implants, on microencapsulation or on the preparation of porous biodegradable matrixes, for example in the form of microparticles of various grain sizes. In this respect, one can mention EP-A-0052510 for microencapsulation and EP-A-0058481 or US-A-3,976,071 for the preparation of implants or of porous biodegradable matrixes. All these techniques make use of a preliminary dissolution in an ,~
.
More precisely, the object of the invention is a method for preparing a pharmaceutical composition which is aimed at providing a prolonged and a controlled release of a medicamentous substance, which is obtained in the form of microparticles of a copolymer of lactic and of glycolic acids, and which incorporates, as the active substance, the pamoate, tannate, stearate or palmitate of a natural or of a synthetic peptide and, more particularly, of a peptide comprising 3 to 45 amino acids.
STATE OF TXE ART
Various solutions have been proposed to this day for preparing compositions ensuring a prolonged and a controlled release of medicamentous substances, which are based on the preparation of biodegradable implants, on microencapsulation or on the preparation of porous biodegradable matrixes, for example in the form of microparticles of various grain sizes. In this respect, one can mention EP-A-0052510 for microencapsulation and EP-A-0058481 or US-A-3,976,071 for the preparation of implants or of porous biodegradable matrixes. All these techniques make use of a preliminary dissolution in an ,~
.
- 2 - ~ 02 1 767 organic solvent of the biodegradable polymer or copolymer used as support, and, when required, the dissolution of the medicamentous substance itself. Even though the dispersion of the active substance throughout the biodegradable mass is satisfactory in such cases, problems with trace amounts of residual solvent are always encountered, which may jeopardize the use of such compositions in therapeutic applications. The selection of solvents with a low toxicity or the thorough removal of traces of solvent can sometimes be complex and expensive, or it can result in an unacceptable loss of purity of the product.
It has also been proposed to dry-mix - i. e. without any solvent - a proteinic substance (Bovine Serum Albumine) and a biodegradable copolymer of lactic and of glycolic acids in the form of powders, and then to carry out a compression at the melting temperature of the mixture thus obtained (J. D. Gresser and al., Biopolymeric Controlled Release System Vol. II, p. 136). This technique did not prove satisfactory, in particular with respect to the homogeneity of the distribution of the proteinic substance (BSA) throughout the mass.
Against all expectations, it was found that these various problems could be overcome even when using as starting material the same type of biodegradable polymers or copolymers and of natural or synthetic peptides, such as octa-, nona-, or decapeptides, and more generally peptides comprising 3 to 45 amino acids, through the application of the method of the invention.
PREFERRED ENBODIMENTS OF THE lNv~NlION
According to the invention, natural or synthetic peptides are used in the form of salts, more precisely as pamoates, tannates, stearates or palmitates, and preferably as pamoates. It can be noted in this respect, that these salts of peptides are insoluble in water.
It has also been proposed to dry-mix - i. e. without any solvent - a proteinic substance (Bovine Serum Albumine) and a biodegradable copolymer of lactic and of glycolic acids in the form of powders, and then to carry out a compression at the melting temperature of the mixture thus obtained (J. D. Gresser and al., Biopolymeric Controlled Release System Vol. II, p. 136). This technique did not prove satisfactory, in particular with respect to the homogeneity of the distribution of the proteinic substance (BSA) throughout the mass.
Against all expectations, it was found that these various problems could be overcome even when using as starting material the same type of biodegradable polymers or copolymers and of natural or synthetic peptides, such as octa-, nona-, or decapeptides, and more generally peptides comprising 3 to 45 amino acids, through the application of the method of the invention.
PREFERRED ENBODIMENTS OF THE lNv~NlION
According to the invention, natural or synthetic peptides are used in the form of salts, more precisely as pamoates, tannates, stearates or palmitates, and preferably as pamoates. It can be noted in this respect, that these salts of peptides are insoluble in water.
- 3 - 20~1767 The above-mentioned salts, as well as the copolymers of lactic acid (L- or D,L-lactic acid) and of glycolic acid are used in the form of a powder, and more particularly, in the form of microparticles with an average grain size below approximately 200 microns. Good results were obtained with microparticles of copolymer with a grain size in the order of 180 microns or less, the peptidic salt being capable of having even a smaller grain size. The mixture of these materials is carried out by dry-mixing in any appropriate apparatus, for example in a ball mill, and at room temperature (approx. 25C) or even at a lower temperature, for example 5 to 10C. The proportion of the powdered components can vary within a broad range, for example from 0.1 to 15% in weight for the peptidic salt, depending upon the therapeutic effects required.
According to the invention, once a given mixture is duly homogenized, it is subjected to a progressive compression and, simultaneously, to a progressive heating, before being extruded. These two operations, as well as the transport of the mixture to the precompression and preheating zone can be carried out advantageously using an adequately dimensioned endless screw. The compression ratio may vary depending on numerous factors, such as the geometry of the apparatus or the grain size of the powdered mixture. The control of the preheating and of the change it undergoes as the mixture progresses is more critical : depending upon the nature of the products to be treated (copolymer, peptide), every endeavour is made to maintain a temperature gradient not exceeding approximately 80C. The initial temperature to which the powdered mixture is subjected can be 25C, lower or higher, depending on circumstances.
The mixture thus precompressed and preheated is then subjected to an extrusion at a temperature most generally comprised between approximately 80 and 100C, the upper limit of this range being dictated by the nature of the medicamentous substance (peptide), which should not undergo deterioration. The extrusion can be carried out at a pressure which can vary considerably in the range from 50 to 500 kg/cm2, the main point being that the extrusion temperature and pressure be adapted according to the viscosity of the product. Quite obviously, an adequate pressure and an adequate temperature promote the perfect homogenization of the ingredients and, in particular, the regular distribution of the peptidic salt throughout the mass of the copolymer.
The actual extrusion is carried out by means of a nozzle of standard shape and dimensions, placed at the downstream end of the above-mentioned endless screw. The cooling of the extruded product is achieved by any appropriate means, such as cold sterile air or gas or simply through natural loss of heat.
According to the invention, the extruded product adequately cooled is then pulverized at low temperature, preferably at a temperature lower than 0C, or even much lower, for example -10C or -30C. It is advantageous to use cryogenic pulverization, a technique known per se.
The product thus pulverized is then subjected to a grading of the microparticles according to their average grain size, those having a grain size below 200 microns and preferably below or equal to 180 microns being retained, in accordance with the method of the invention. The grading of the microparticles can be carried out, for example, by sieving. The graded microparticles are collected and they are then ready for use.
In accordance with the method of the invention, the steps described above take place in succession, without any excessive delay between two successive steps. An advantage of this method is that it can also be carried out as a continuous process, with all the operations taking place in succession, simply by transferring the treated mixture.
According to the invention, one can use as copolymer of lactic and glycolic acids, any type of biodegradable copolymer comprised of such a base, and preferably, a copolymer of L- or D,L-lactic acid containing respectively from 45% to 90% (moles) of lactic acid units and 55% to 10% (moles) of glycolic acid units. Such polymers are readily prepared as described in the above-mentioned literature or they can be obtained from specialized firms.
The salts of peptides, whether natural or synthetic, thus incorporated into the mass of the copolymer, are preferably salts of peptides comprising from 3 to 45 amino acids and, more particularly, salts of LH-RH (Luteinizing Hormone - Releasing Hormone), of somatostatin, of GH-RH
(Growth Hormone - Releasing Hormone) or of calcitonin, or of their synthetic homologues or analogues.
More particularly, the pamoate of LH-RH, of somatostatin or of one of their homologues or analogues selected from D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OH, D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Trp-NH2, D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2, D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2, D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2, AcPhe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2, AcPhe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2, (pyro)Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2, (pyro)Glu-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH2, (pyro)Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR1 or (pyro)Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHR1 (R1 = lower alkyl) are concerned, this list not being limitative.
The microparticles obtained according to the method of the invention from the above-mentioned ingredients are then used, after an appropriate sterilization, for the preparation of injectable suspensions.
The following Examples illustrate the invention in a more detailed manner, without however limiting its scope.
Example 1 20 g of a 50:50 (% moles) copolymer of D,L-lactic and glycolic acids in the form of granules having a diameter ranging approximately from 3 to 5 mm were first milled at low temperature and sieved to obtain microparticles having an average grain size of 180 microns or less.
To this powdered mass, were added 0.490g of finely pulverized pamoate of D-Trp6-LH-RH (formula of the peptide :
(pyro)Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2).
The product is comprised of microparticles with a grain size of about 10 microns and it has an amorphous structure. The resulting mixture was homogenized in a mill at room temperature.
The homogenized mixture was then placed inside an apparatus provided with an endless screw coupled to a conventional extrusion nozzle. The endless screw can have a length of about 25 cm and a diameter of about 1.5 cm. It includes a first zone, the purpose of which is exclusively ~ 7 ~ 2021767 to move the mixture, and which neighbours a second zone designed for the compression and the preheating.
As the mixture travels, it is heated from 25 to approximately 80, the travelling speed being adjusted so that this phase lasts about 5 minutes. The actual extrusion takes place at 98C, through an extrusion nozzle having an opening with a diameter of approximately 1.5 mm.
The filaments thus obtained are then left to cool at room temperature, cut into short portions and finally milled at -30C. After sieving, microparticles with an average grain size of 180 microns or less are collected.
The chemical analysis, carried out on samples of the product after extrusion and milling, confirms the perfect homogeneity of the dispersion of the active substance throughout the mass of the polymer.
The microparticles obtained above were subjected to a sterilization with gamma rays and then they were suspended in an appropriate sterile vehicle. In vivo tests (determination of the level of blood testosterone in strains of male rats) confirm the regular release of the active substance during at least 25 days, which results in a fall of testosterone to castration levels.
Example 2 Microparticles of a 50:50 (~ moles) copolymer of D,L-lactic-glycolic acids were prepared according to the procedure of Example 1, to include a comparable level of pamoate of one of the following decapeptides :
(pyro) Glu-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH2, (pyro) Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR1 or (pyro) Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHR
1 = ethyl) The activity tests carried out in vivo confirm a regular release of the active substance over several weeks.
Example 3 13.85 g of a 75:25 (% moles) copolymer of D,L-lactic and glycolic acids in the form of granules with a diameter in the order of 3 to 5 mm were first milled at low temperature and sieved to obtain microparticles with an average grain size of 180 microns or less.
To this powdered mass, 1.15 g of finely pulverized pamoate of D-Trp6-LH-RH (formula of the peptide :
(pyro)Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2), were added. The product consists of microcapsules with a grain size of about 10 microns and it has an amorphous structure. The resulting mixture was homogenized at room temperature in a mill, and finally subjected to the treatment described in Example 1.
After cryopulverizing, sieving and finally sterilizing with gamma rays, the microparticles were suspended in an appropriate sterile vehicle. In vivo tests (determination of the level of blood testosterone in strains of male rats) confirm the regular release of the active substance during at least 40 days, which results in a fall of testosterone to castration levels.
Example 4 The procedure of Example 1 was followed, starting from 18 g of the 50:50 (% moles) copolymer of D,L-lactic and glycolic acids and from 2.85 g of pamoate of an analogue of somatostatin - formula of the peptide :
2Q~1767 g D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 to obtain microparticles having the desired grain size.
The chemical analysis carried out on the samples of the product after extrusion and milling, confirm the perfect homogeneity of the dispersion of the active substance throughout the mass of the copolymer.
In vivo tests further confirm the controlled release of the active substance (analogue of somatostatin) over a period of at least 7 days.
Example 5 The procedure of Example 4 was repeated, starting this time from 13.50 g of a 75:25 copolymer of D,L-lactic-glycolic acids and from 1.50 g of pamoate of the above-mentioned analogue of somatostatin.
The microparticles thus obtained, once sterilized by means of gamma rays, were finally suspended in an appropriate sterile vehicle. In vivo tests (determination of the level of the analogue of somatostatin in blood serum of rats subjected to a single injection at to) indicate a controlled release of the active substance during at least 15 days.
Example 6 The procedure of Example 4 was used, to obtain microparticles of a 50:50 (% moles) copolymer of D,L-lactic-glycolic acids, containing a similar amount of pamoate of one of the following octapeptides :
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OH, 20~1767 D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Trp-NH2, D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2, D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2, AcPhe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2, AcPhe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2.
The chemical analysis carried out on samples of the product after extrusion and milling, confirms the perfect homogeneity of the dispersion of the active substance throughout the mass of the copolymer.
* * * * * *
During the above-described experimentation, it was noted that the extruded filaments, once cut into short rods of an appropriate length, could be used directly as implants, after sterilization. Such implants ensure also a prolonged and a controlled release of the active substance.
According to the invention, once a given mixture is duly homogenized, it is subjected to a progressive compression and, simultaneously, to a progressive heating, before being extruded. These two operations, as well as the transport of the mixture to the precompression and preheating zone can be carried out advantageously using an adequately dimensioned endless screw. The compression ratio may vary depending on numerous factors, such as the geometry of the apparatus or the grain size of the powdered mixture. The control of the preheating and of the change it undergoes as the mixture progresses is more critical : depending upon the nature of the products to be treated (copolymer, peptide), every endeavour is made to maintain a temperature gradient not exceeding approximately 80C. The initial temperature to which the powdered mixture is subjected can be 25C, lower or higher, depending on circumstances.
The mixture thus precompressed and preheated is then subjected to an extrusion at a temperature most generally comprised between approximately 80 and 100C, the upper limit of this range being dictated by the nature of the medicamentous substance (peptide), which should not undergo deterioration. The extrusion can be carried out at a pressure which can vary considerably in the range from 50 to 500 kg/cm2, the main point being that the extrusion temperature and pressure be adapted according to the viscosity of the product. Quite obviously, an adequate pressure and an adequate temperature promote the perfect homogenization of the ingredients and, in particular, the regular distribution of the peptidic salt throughout the mass of the copolymer.
The actual extrusion is carried out by means of a nozzle of standard shape and dimensions, placed at the downstream end of the above-mentioned endless screw. The cooling of the extruded product is achieved by any appropriate means, such as cold sterile air or gas or simply through natural loss of heat.
According to the invention, the extruded product adequately cooled is then pulverized at low temperature, preferably at a temperature lower than 0C, or even much lower, for example -10C or -30C. It is advantageous to use cryogenic pulverization, a technique known per se.
The product thus pulverized is then subjected to a grading of the microparticles according to their average grain size, those having a grain size below 200 microns and preferably below or equal to 180 microns being retained, in accordance with the method of the invention. The grading of the microparticles can be carried out, for example, by sieving. The graded microparticles are collected and they are then ready for use.
In accordance with the method of the invention, the steps described above take place in succession, without any excessive delay between two successive steps. An advantage of this method is that it can also be carried out as a continuous process, with all the operations taking place in succession, simply by transferring the treated mixture.
According to the invention, one can use as copolymer of lactic and glycolic acids, any type of biodegradable copolymer comprised of such a base, and preferably, a copolymer of L- or D,L-lactic acid containing respectively from 45% to 90% (moles) of lactic acid units and 55% to 10% (moles) of glycolic acid units. Such polymers are readily prepared as described in the above-mentioned literature or they can be obtained from specialized firms.
The salts of peptides, whether natural or synthetic, thus incorporated into the mass of the copolymer, are preferably salts of peptides comprising from 3 to 45 amino acids and, more particularly, salts of LH-RH (Luteinizing Hormone - Releasing Hormone), of somatostatin, of GH-RH
(Growth Hormone - Releasing Hormone) or of calcitonin, or of their synthetic homologues or analogues.
More particularly, the pamoate of LH-RH, of somatostatin or of one of their homologues or analogues selected from D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OH, D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Trp-NH2, D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2, D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2, D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2, AcPhe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2, AcPhe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2, (pyro)Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2, (pyro)Glu-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH2, (pyro)Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR1 or (pyro)Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHR1 (R1 = lower alkyl) are concerned, this list not being limitative.
The microparticles obtained according to the method of the invention from the above-mentioned ingredients are then used, after an appropriate sterilization, for the preparation of injectable suspensions.
The following Examples illustrate the invention in a more detailed manner, without however limiting its scope.
Example 1 20 g of a 50:50 (% moles) copolymer of D,L-lactic and glycolic acids in the form of granules having a diameter ranging approximately from 3 to 5 mm were first milled at low temperature and sieved to obtain microparticles having an average grain size of 180 microns or less.
To this powdered mass, were added 0.490g of finely pulverized pamoate of D-Trp6-LH-RH (formula of the peptide :
(pyro)Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2).
The product is comprised of microparticles with a grain size of about 10 microns and it has an amorphous structure. The resulting mixture was homogenized in a mill at room temperature.
The homogenized mixture was then placed inside an apparatus provided with an endless screw coupled to a conventional extrusion nozzle. The endless screw can have a length of about 25 cm and a diameter of about 1.5 cm. It includes a first zone, the purpose of which is exclusively ~ 7 ~ 2021767 to move the mixture, and which neighbours a second zone designed for the compression and the preheating.
As the mixture travels, it is heated from 25 to approximately 80, the travelling speed being adjusted so that this phase lasts about 5 minutes. The actual extrusion takes place at 98C, through an extrusion nozzle having an opening with a diameter of approximately 1.5 mm.
The filaments thus obtained are then left to cool at room temperature, cut into short portions and finally milled at -30C. After sieving, microparticles with an average grain size of 180 microns or less are collected.
The chemical analysis, carried out on samples of the product after extrusion and milling, confirms the perfect homogeneity of the dispersion of the active substance throughout the mass of the polymer.
The microparticles obtained above were subjected to a sterilization with gamma rays and then they were suspended in an appropriate sterile vehicle. In vivo tests (determination of the level of blood testosterone in strains of male rats) confirm the regular release of the active substance during at least 25 days, which results in a fall of testosterone to castration levels.
Example 2 Microparticles of a 50:50 (~ moles) copolymer of D,L-lactic-glycolic acids were prepared according to the procedure of Example 1, to include a comparable level of pamoate of one of the following decapeptides :
(pyro) Glu-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH2, (pyro) Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR1 or (pyro) Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHR
1 = ethyl) The activity tests carried out in vivo confirm a regular release of the active substance over several weeks.
Example 3 13.85 g of a 75:25 (% moles) copolymer of D,L-lactic and glycolic acids in the form of granules with a diameter in the order of 3 to 5 mm were first milled at low temperature and sieved to obtain microparticles with an average grain size of 180 microns or less.
To this powdered mass, 1.15 g of finely pulverized pamoate of D-Trp6-LH-RH (formula of the peptide :
(pyro)Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2), were added. The product consists of microcapsules with a grain size of about 10 microns and it has an amorphous structure. The resulting mixture was homogenized at room temperature in a mill, and finally subjected to the treatment described in Example 1.
After cryopulverizing, sieving and finally sterilizing with gamma rays, the microparticles were suspended in an appropriate sterile vehicle. In vivo tests (determination of the level of blood testosterone in strains of male rats) confirm the regular release of the active substance during at least 40 days, which results in a fall of testosterone to castration levels.
Example 4 The procedure of Example 1 was followed, starting from 18 g of the 50:50 (% moles) copolymer of D,L-lactic and glycolic acids and from 2.85 g of pamoate of an analogue of somatostatin - formula of the peptide :
2Q~1767 g D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 to obtain microparticles having the desired grain size.
The chemical analysis carried out on the samples of the product after extrusion and milling, confirm the perfect homogeneity of the dispersion of the active substance throughout the mass of the copolymer.
In vivo tests further confirm the controlled release of the active substance (analogue of somatostatin) over a period of at least 7 days.
Example 5 The procedure of Example 4 was repeated, starting this time from 13.50 g of a 75:25 copolymer of D,L-lactic-glycolic acids and from 1.50 g of pamoate of the above-mentioned analogue of somatostatin.
The microparticles thus obtained, once sterilized by means of gamma rays, were finally suspended in an appropriate sterile vehicle. In vivo tests (determination of the level of the analogue of somatostatin in blood serum of rats subjected to a single injection at to) indicate a controlled release of the active substance during at least 15 days.
Example 6 The procedure of Example 4 was used, to obtain microparticles of a 50:50 (% moles) copolymer of D,L-lactic-glycolic acids, containing a similar amount of pamoate of one of the following octapeptides :
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OH, 20~1767 D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Trp-NH2, D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2, D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2, AcPhe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2, AcPhe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2.
The chemical analysis carried out on samples of the product after extrusion and milling, confirms the perfect homogeneity of the dispersion of the active substance throughout the mass of the copolymer.
* * * * * *
During the above-described experimentation, it was noted that the extruded filaments, once cut into short rods of an appropriate length, could be used directly as implants, after sterilization. Such implants ensure also a prolonged and a controlled release of the active substance.
Claims (25)
1. A method for preparing a pharmaceutical composition which is aimed at providing a prolonged and a controlled release of medicamentous substance, which is obtained in the form of microparticles of a copolymer of lactic and glycolic acids, and which incorporates, as the active substance, the pamoate, tannate, stearate or palmitate salt of a natural or of a synthetic peptide, characterized in that:
a) the selected copolymer and active substance, both present in the form of microparticles whose average grain size is below approximately 200 microns, are dry-mixed in relative amounts such that the active substance is present in a proportion of about 0.1-15% by weight;
b) the powdered mixture thus obtained is compressed and is heated up to approximately 80°C;
c) the precompressed and preheated mixture is subjected to an extrusion at a temperature of between approximately 80° and 100°C; and d) the product resulting from the extrusion is pulverized at low temperature and then, the microparticles having a grain size below approximately 200 microns are selected and finally collected.
a) the selected copolymer and active substance, both present in the form of microparticles whose average grain size is below approximately 200 microns, are dry-mixed in relative amounts such that the active substance is present in a proportion of about 0.1-15% by weight;
b) the powdered mixture thus obtained is compressed and is heated up to approximately 80°C;
c) the precompressed and preheated mixture is subjected to an extrusion at a temperature of between approximately 80° and 100°C; and d) the product resulting from the extrusion is pulverized at low temperature and then, the microparticles having a grain size below approximately 200 microns are selected and finally collected.
2. A method according to claim 1, characterized in that the microparticles of copolymer have an average grain size below or equal to 180 microns.
3. A method according to claim 2, characterized in that the precompression and the preheating of the mixture are carried out simultaneously by means of an endless screw.
4. A method according to claim 3, characterized in that the extrusion is carried out at a pressure in the range from 50 to 500 kg/cm2.
5. A method according to claim 4, characterized in that the pulverization of the product resulting from the extrusion is a cryogenic pulverization.
6. A method according to claim 5, characterized in that the selection of the microparticles resulting from the pulverization is carried out by sieving.
7. A method according to claim 6, characterized in that the copolymer of lactic and glycolic acids is a copolymer of L- or D, L-lactic acid containing respectively 45 to 90%
(moles) of lactic acid units and 55 to 10% (moles) of glycolic acid units.
(moles) of lactic acid units and 55 to 10% (moles) of glycolic acid units.
8. A method according to claim 7, characterized in that the active substance is the pamoate, tannate, stearate or palmitate of a natural or of a synthetic peptide comprising 3 to 45 amino acids, and including LH-RH, somatostatin, GH-RH, calcitonin or one of their synthetic analogues or homologues.
9. A method according to claim 8, characterized in that the active substance is a pamoate of LH-RH, of somatostatin or of one of their analogues or homologues selected from , or (R1 = lower alkyl).
10. A pharmaceutical composition in the form of microparticles obtained by the method of any one of claims 1 to 9.
11. The use of a pharmaceutical composition according to claim 10 for the preparation of injectable suspensions.
12. A method for preparing a pharmaceutical composition which provides a prolonged and controlled release of an active substance, which comprises:
a) mixing microparticles of a copolymer of lactic and glycolic acids with microparticles of an active substance of an insoluble salt of a natural or synthetic peptide comprising 3 to 45 amino acids for a sufficient time to form a homogenous mixture containing about 0.1 to 15% by weight of the active substance, each of said micropar-ticles having an average grain size of below approxi-mately 200 microns; and b) precompressing and preheating the mixture prior to extruding the precompressed and preheated mixture at a temperature of between approximately 80° and 100°C to form a product for use as said pharmaceutical composition.
a) mixing microparticles of a copolymer of lactic and glycolic acids with microparticles of an active substance of an insoluble salt of a natural or synthetic peptide comprising 3 to 45 amino acids for a sufficient time to form a homogenous mixture containing about 0.1 to 15% by weight of the active substance, each of said micropar-ticles having an average grain size of below approxi-mately 200 microns; and b) precompressing and preheating the mixture prior to extruding the precompressed and preheated mixture at a temperature of between approximately 80° and 100°C to form a product for use as said pharmaceutical composition.
13. A method according to claim 12 which further comprises:
c) pulverizing the extruded product at low temperature; and d) selecting the microparticles which have a grain size of below about 200 microns for use as said pharmaceutical composition.
c) pulverizing the extruded product at low temperature; and d) selecting the microparticles which have a grain size of below about 200 microns for use as said pharmaceutical composition.
14. A method according to claim 13 which further comprises selecting the microparticles of the copolymer to have an average grain size of 180 microns or less.
15. A method according to claim 13 wherein the precompressing and preheating of the mixture are carried out simultaneously by passing the mixture through an endless screw.
16. A method according to claim 13 wherein the extrusion is carried out at a pressure in the range of about 50 to 500 kg/cm2.
17. A method according to claim 13 which further comprises pulverizing the extruded product at cryogenic temperatures.
18. A method according to claim 13 wherein the selection of the microparticles for use as the pharmaceutical composition is obtained by sieving the desired grain size of the pulverized product.
19. A method according to claim 13 which further comprises selecting the copolymer of lactic and glycolic acids to be a copolymer of L- or D,L-lactic acid containing 45 to 90% (moles) of lactic acid units and 55 to 10% (moles) of glycolic acid units.
20. A method according to claim 13 which further comprises selecting the active substance to be a pamoate, tannate, stearate or palmitate salt of LH-RH, somatostatin, GH-RH, calcitonin or a synthetic analogue or homologue thereof.
21. A method according to claim 13 which further comprises selecting the active substance to be a pamoate salt of LH-RH, somatostatin or an analogue or homologue thereof selected from the group consisting of:
or .
where R1 = a lower alkyl group.
or .
where R1 = a lower alkyl group.
22. The method of claim 1 wherein additional heat and pressure are simultaneously applied in slowly increasing amounts to the powdered mixture of the selected copolymer and active substance.
23. The method of claim 22 wherein additional heat and pressure are simultaneously applied in slowly increasing amounts to the powdered mixture of the selected copolymer and active substance as the mixture is transported in an endless screw.
24. The method of claim 12 wherein additional heat and pressure are simultaneously applied in slowly increasing amounts to the powdered mixture of the selected copolymer and active substance.
25. The method of claim 24 wherein additional heat and pressure are simultaneously applied in slowly increasing amounts to the powdered mixture of the selected copolymer and active substance as the mixture is transported in an endless screw.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2829/89-2 | 1989-07-28 | ||
| CH2829/89A CH679207A5 (en) | 1989-07-28 | 1989-07-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2021767A1 CA2021767A1 (en) | 1991-01-29 |
| CA2021767C true CA2021767C (en) | 1996-10-22 |
Family
ID=4242536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002021767A Expired - Lifetime CA2021767C (en) | 1989-07-28 | 1990-07-23 | Method for preparing a pharmaceutical composition in the form of microparticles |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5134122A (en) |
| JP (1) | JPH0662427B2 (en) |
| AT (1) | AT397197B (en) |
| AU (1) | AU619996B2 (en) |
| BE (1) | BE1003093A3 (en) |
| CA (1) | CA2021767C (en) |
| CH (1) | CH679207A5 (en) |
| DE (1) | DE4023134C2 (en) |
| DK (1) | DK175495B1 (en) |
| ES (1) | ES2020890A6 (en) |
| FI (1) | FI97688C (en) |
| FR (1) | FR2650182B1 (en) |
| GB (1) | GB2234169B (en) |
| GR (1) | GR1001215B (en) |
| IE (1) | IE65397B1 (en) |
| IL (1) | IL95120A (en) |
| IT (1) | IT1243357B (en) |
| LU (1) | LU87772A1 (en) |
| NL (1) | NL194858C (en) |
| NO (1) | NO300304B1 (en) |
| PT (1) | PT94842B (en) |
| SE (1) | SE504279C2 (en) |
| ZA (1) | ZA905654B (en) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| CH681425A5 (en) * | 1990-11-14 | 1993-03-31 | Debio Rech Pharma Sa | |
| US6517859B1 (en) | 1990-05-16 | 2003-02-11 | Southern Research Institute | Microcapsules for administration of neuroactive agents |
| DE69133136T2 (en) * | 1990-05-16 | 2003-06-18 | Southern Res Inst Birmingham | MICROCAPSULES WITH CONTROLLED RELEASE AND THEIR USE FOR STIMULATING NERVOUS FIBER GROWTH |
| CH683149A5 (en) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Process for the preparation of microspheres of a biodegradable polymeric material. |
| WO1993015722A1 (en) * | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| US5876452A (en) * | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
| US6013853A (en) * | 1992-02-14 | 2000-01-11 | The University Of Texas System | Continuous release polymeric implant carrier |
| GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5456917A (en) * | 1993-04-12 | 1995-10-10 | Cambridge Scientific, Inc. | Method for making a bioerodible material for the sustained release of a medicament and the material made from the method |
| DE4342092B4 (en) * | 1993-12-09 | 2007-01-11 | Zentaris Gmbh | Long-acting suspension for injection and method of preparation |
| CA2178592C (en) * | 1993-12-09 | 2009-07-28 | Jurgen Engel | Long-acting injection suspensions and a process for their preparation |
| US5569468A (en) * | 1994-02-17 | 1996-10-29 | Modi; Pankaj | Vaccine delivery system for immunization, using biodegradable polymer microspheres |
| US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| US5430021A (en) * | 1994-03-18 | 1995-07-04 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
| US5595760A (en) * | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| FR2748205A1 (en) | 1996-05-06 | 1997-11-07 | Debio Rech Pharma Sa | PHARMACEUTICAL COMPOSITIONS FOR THE CONTROLLED RELEASE OF INSOLUBLE ACTIVE SUBSTANCES |
| US5945128A (en) * | 1996-09-04 | 1999-08-31 | Romano Deghenghi | Process to manufacture implants containing bioactive peptides |
| CA2267930A1 (en) * | 1996-10-09 | 1998-04-16 | Nobuyuki Takechi | A method for producing a microparticle |
| WO1998032423A1 (en) * | 1997-01-29 | 1998-07-30 | Takeda Chemical Industries, Ltd. | Sustained-release microspheres, their production and use |
| US6071982A (en) * | 1997-04-18 | 2000-06-06 | Cambridge Scientific, Inc. | Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same |
| US6573238B2 (en) | 1997-11-07 | 2003-06-03 | Chiron Corporation | Method for producing sustained-release formulations |
| IT1304152B1 (en) * | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | COMPOSITIONS INCLUDING A PEPTIDE AND POLYLACTIC-GLYCOLIC ACID FOR THE PREPARATION OF SUBCUTANEOUS IMPLANTS HAVING A PROLONGED |
| US6455526B1 (en) | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
| EE200100314A (en) * | 1998-12-16 | 2002-08-15 | Aventis Pharmaceuticals Inc. | A method of making a pharmaceutical composition, a pharmaceutical composition and its use |
| CA2689696C (en) | 1999-02-26 | 2013-08-06 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
| US7713739B1 (en) | 2000-11-17 | 2010-05-11 | Novartis Vaccines And Diagnostics, Inc. | Microparticle-based transfection and activation of dendritic cells |
| ES2169980B1 (en) | 1999-12-17 | 2003-11-01 | Lipotec Sa | MICROCAPSULES FOR THE PROLONGED RELEASE OF PHARMACOS. |
| US6362308B1 (en) | 2000-08-10 | 2002-03-26 | Alkermes Controlled Therapeutics Inc. Ii | Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content |
| US20040022853A1 (en) * | 2001-04-26 | 2004-02-05 | Control Delivery Systems, Inc. | Polymer-based, sustained release drug delivery system |
| NZ528994A (en) * | 2001-04-26 | 2006-02-24 | Control Delivery Sys Inc | Sustained release drug delivery system containing codrugs |
| EP1392248B1 (en) * | 2001-05-23 | 2007-08-08 | Hexal Ag | Implant manufacturing process by means of solvent free preparation of a homogenate |
| AU2002324447B2 (en) | 2001-06-22 | 2006-06-29 | Durect Corporation | Zero-order prolonged release coaxial implants |
| IN2014DN10834A (en) * | 2001-09-17 | 2015-09-04 | Psivida Inc | |
| EP1532985B1 (en) * | 2002-06-25 | 2016-10-12 | Takeda Pharmaceutical Company Limited | Process for producing a sustained-release composition |
| BR122018074353B8 (en) | 2003-01-28 | 2021-07-27 | Ironwood Pharmaceuticals Inc | pharmaceutical composition, polypeptide and methods for producing them |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| GB0304726D0 (en) * | 2003-03-01 | 2003-04-02 | Ardana Bioscience Ltd | New Process |
| WO2004096259A1 (en) * | 2003-04-30 | 2004-11-11 | Debiopharm S.A. | Methods and compositions using gonadotropin hormone releasing hormone |
| US9149440B2 (en) * | 2003-09-02 | 2015-10-06 | University Of South Florida | Nanoparticles for drug-delivery |
| ATE551339T1 (en) | 2003-11-05 | 2012-04-15 | Sarcode Bioscience Inc | MODULATORS OF CELLULAR ADHESION |
| WO2005063276A1 (en) * | 2003-12-23 | 2005-07-14 | Debiopharm S.A. | Methods and compositions using gonadotropin hormone releasing hormone |
| FR2865938B1 (en) | 2004-02-05 | 2006-06-02 | Sod Conseils Rech Applic | SOLID DELAY FORMULATION COMPRISING TRIPTORELINE ACETATE |
| US8541028B2 (en) | 2004-08-04 | 2013-09-24 | Evonik Corporation | Methods for manufacturing delivery devices and devices thereof |
| AU2005279772A1 (en) | 2004-08-30 | 2006-03-09 | Spineovations, Inc. | Method of treating spinal internal disk derangement |
| EP1674082A1 (en) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Process for the manufacture of sterile suspensions or lyophilisates of low-soluble basic peptide complexes, pharmaceutical formulations comprising these complexes and their use as medicament |
| SI1881823T1 (en) | 2005-05-17 | 2015-04-30 | Sarcode Bioscience Inc. | Compositions and methods for treatment of eye disorders |
| KR100722607B1 (en) | 2006-05-11 | 2007-05-28 | 주식회사 펩트론 | A process of preparing microspheres for sustained release having improved dispersibility and syringeability |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| CN101772513B (en) | 2007-06-04 | 2013-11-13 | 协同医药品公司 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| DK2500014T3 (en) | 2007-06-06 | 2018-12-03 | Debiopharm Res & Manufacturing Sa | Slow release pharmaceutical composition made from microparticles |
| CA3105972A1 (en) * | 2007-10-19 | 2009-04-30 | Novartis Ag | Compositions and methods for treatment of diabetic retinopathy |
| US8728528B2 (en) | 2007-12-20 | 2014-05-20 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| US20100010549A1 (en) * | 2008-03-05 | 2010-01-14 | Neville Alleyne | device and method of minimally invasive extracapsular ligamentous augmentation for canine stifle ligament injuries |
| US8469961B2 (en) * | 2008-03-05 | 2013-06-25 | Neville Alleyne | Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints |
| CN102065893A (en) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | Delivery of LFA-1 antagonists to the gastrointestinal system |
| WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| ES2522968T3 (en) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JP2011528375A (en) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders |
| EP2421517A4 (en) * | 2009-04-23 | 2013-08-07 | Sustained Nano Systems Llc | Controlled release dispensing device |
| WO2011050175A1 (en) * | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| KR101411349B1 (en) | 2010-12-24 | 2014-06-25 | 주식회사 삼양바이오팜 | Microparticles containing physiologically active peptide and method for preparing the same, and pharmaceutical composition comprising the same |
| CN103635446B (en) | 2011-05-04 | 2016-02-03 | 巴兰斯医疗公司 | Yetrazol derivative |
| EP2630964A1 (en) * | 2012-02-22 | 2013-08-28 | Immundiagnostik AG | Method and medicament for treating patients in risk of prediabetes and type-2 diabetes |
| US10071061B2 (en) | 2012-05-14 | 2018-09-11 | Teijin Limited | Sterile composition |
| EP2877465A4 (en) | 2012-07-25 | 2016-05-11 | Sarcode Bioscience Inc | Lfa-1 inhibitor and polymorph thereof |
| AU2014218599C1 (en) | 2013-02-25 | 2018-09-06 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists for use in colonic cleansing |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| JP2016514671A (en) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists and uses thereof |
| CA2926358A1 (en) * | 2013-10-08 | 2015-04-16 | Ferring B.V. | Microparticles comprising gnrh made by pgss |
| CA2926691A1 (en) | 2013-10-10 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
| ES2693579T3 (en) | 2015-01-16 | 2018-12-12 | Spineovations, Inc. | Method of treatment of the intervertebral disc |
| EP3402804A1 (en) | 2016-01-11 | 2018-11-21 | Synergy Pharmaceuticals Inc. | Formulations and methods for treating ulcerative colitis |
| CN110913907A (en) | 2017-07-11 | 2020-03-24 | 持续纳米系统有限责任公司 | Hyper-compressed pharmaceutical formulation |
| BR112020000504A2 (en) | 2017-07-11 | 2020-07-14 | Sustained Nano Systems Llc | radiation sterilization of hyper-compressed polymer dosage forms |
| CA3077011A1 (en) | 2017-09-26 | 2019-04-04 | Nanomi B.V. | Method for preparing micro-particles by double emulsion technique |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3976071A (en) * | 1974-01-07 | 1976-08-24 | Dynatech Corporation | Methods of improving control of release rates and products useful in same |
| US3978203A (en) * | 1974-07-12 | 1976-08-31 | Dynatech Corporation | Sustained release of pharmaceuticals from polyester matrices |
| US4107288A (en) * | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US4010125A (en) * | 1975-06-12 | 1977-03-01 | Schally Andrew Victor | [D-Trp6 ]-LH-RH and intermediates therefor |
| US4622244A (en) * | 1979-09-04 | 1986-11-11 | The Washington University | Process for preparation of microcapsules |
| PH19942A (en) * | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4349530A (en) * | 1980-12-11 | 1982-09-14 | The Ohio State University | Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal |
| US4483807A (en) * | 1981-01-27 | 1984-11-20 | Japan Atomic Energy Research Institute | Process for producing a slow release composite |
| IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| CH661206A5 (en) * | 1983-09-23 | 1987-07-15 | Debiopharm Sa | PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES. |
| JPS60181029A (en) * | 1984-02-29 | 1985-09-14 | Toyo Jozo Co Ltd | Preparation of sustained release preparation |
| US4666704A (en) * | 1985-05-24 | 1987-05-19 | International Minerals & Chemical Corp. | Controlled release delivery system for macromolecules |
| IL79134A (en) * | 1985-07-29 | 1991-06-10 | American Cyanamid Co | Continuous release peptide implants for parenteral administration |
| US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
| JPS63218632A (en) * | 1987-03-06 | 1988-09-12 | Japan Atom Energy Res Inst | Production of biodegradable copoly(glycolic/l-lactic acid) complex which can gradually release hormons |
| US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| DE3734223A1 (en) * | 1987-10-09 | 1989-04-20 | Boehringer Ingelheim Kg | IMPLANTABLE, BIODEGRADABLE ACTIVE SUBSTANCE RELEASE SYSTEM |
-
1989
- 1989-07-28 CH CH2829/89A patent/CH679207A5/fr not_active IP Right Cessation
-
1990
- 1990-07-16 IE IE259290A patent/IE65397B1/en not_active IP Right Cessation
- 1990-07-17 GB GB9015722A patent/GB2234169B/en not_active Expired - Lifetime
- 1990-07-18 IL IL9512090A patent/IL95120A/en not_active IP Right Cessation
- 1990-07-18 ZA ZA905654A patent/ZA905654B/en unknown
- 1990-07-18 BE BE9000729A patent/BE1003093A3/en not_active IP Right Cessation
- 1990-07-18 AU AU59103/90A patent/AU619996B2/en not_active Expired
- 1990-07-19 NL NL9001646A patent/NL194858C/en not_active IP Right Cessation
- 1990-07-19 FI FI903643A patent/FI97688C/en active IP Right Grant
- 1990-07-20 US US07/555,973 patent/US5134122A/en not_active Expired - Lifetime
- 1990-07-20 DE DE4023134A patent/DE4023134C2/en not_active Expired - Lifetime
- 1990-07-20 FR FR909009333A patent/FR2650182B1/en not_active Expired - Lifetime
- 1990-07-23 IT IT02101990A patent/IT1243357B/en active IP Right Grant
- 1990-07-23 AT AT0154590A patent/AT397197B/en not_active IP Right Cessation
- 1990-07-23 CA CA002021767A patent/CA2021767C/en not_active Expired - Lifetime
- 1990-07-23 ES ES9001976A patent/ES2020890A6/en not_active Expired - Fee Related
- 1990-07-23 NO NO903264A patent/NO300304B1/en not_active IP Right Cessation
- 1990-07-25 GR GR900100568A patent/GR1001215B/en not_active IP Right Cessation
- 1990-07-25 LU LU87772A patent/LU87772A1/en unknown
- 1990-07-27 DK DK199001807A patent/DK175495B1/en not_active IP Right Cessation
- 1990-07-27 PT PT94842A patent/PT94842B/en not_active IP Right Cessation
- 1990-07-27 JP JP2201063A patent/JPH0662427B2/en not_active Expired - Lifetime
- 1990-07-27 SE SE9002522A patent/SE504279C2/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2021767C (en) | Method for preparing a pharmaceutical composition in the form of microparticles | |
| US5225205A (en) | Pharmaceutical composition in the form of microparticles | |
| US5439688A (en) | Process for preparing a pharmaceutical composition | |
| JP2594560B2 (en) | Control of release rate of macromolecular polypeptide | |
| CA1228542A (en) | Lyophilized compositions, preparations and use thereof | |
| JP2966564B2 (en) | Stable compositions for parenteral administration and methods for their preparation | |
| WO1991005548A1 (en) | Sustained release composition for macromolecular proteins | |
| KR101173144B1 (en) | Compositions for repairing bone and methods for preparing and using such compositions | |
| EP0138216B1 (en) | Sustained-release ifn preparation for parenteral administration | |
| JP2004285079A (en) | Sustained-release protein formulation | |
| BG64642B1 (en) | Pharmaceutical composition having continuous release of medicamentous forms capsulated in hyluronic acid microparticles | |
| AU2004251456B2 (en) | Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a PLGA matrix | |
| MXPA05010635A (en) | Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant. | |
| JP2004530696A (en) | Transgenic tissue and homogenite of microparticles | |
| CA2055115A1 (en) | A process for preparing a pharmaceutical composition | |
| EP0314421A1 (en) | Somatotropin formulations | |
| CH685285A5 (en) | Compsn. for sustained and controlled release of peptide salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |